b'quantify the most common cancer-related mutationsReferences(e.g., EGFR, BRAF, KRAS, PIK3CA, JAK2), as well as1.https://www.thermofisher.com/document-connect/document-connect.html?url=https%3A%2F%2Fassets.thermofisher.com%2FTFS-Assets%2FLSGtherapy-resistant mutations (e.g., EGFR T790M). Absolute Q%2Fmanuals%2Fcms_042107.pdfLiquid Biopsy dPCR Assays have been verified to detect allele2.Hurst CD, Zuiverloon TC, Hafner C, Zwarthoff EC, Knowles MA. A SNaPshot frequencies as low as 0.1% and are guaranteed to perform on theassay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene. BMC Res Notes. 2009;2:66. Published 2009 Apr 29. QuantStudio Absolute Q dPCR system. The Absolute Q Liquiddoi:10.1186/1756-0500-2-66Biopsy dPCR Assay run on the QuantStudio Absolute Q Digital3.Reyes GX, Schmidt TT, Kolodner RD, Hombauer H. New insights into the mechanism PCR System provides a precise, cost-effective, and rapid methodof DNA mismatch repair. Chromosoma. 2015;124(4):443-462. doi:10.1007/for monitoring response and resistance to treatment by testing fors00412-015-0514-04.Kang S, Na Y, Joung SY, Lee SI, Oh SC, Min BW. The significance of microsatellite relevant cancer-driver and therapy-resistant mutations. instability in colorectal cancer after controlling for clinicopathological factors. Medicine (Baltimore). 2018;97(9):e0019. doi:10.1097/MD.0000000000010019Conclusions and outlook 5.Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results The Applied Biosystems brand continues to develop innovativeFrom the Phase II KEYNOTE-158 Study. J Clin Oncol. 2020;38(1):1-10. doi:10.1200/tools that facilitate cancer research. For any of the problemsJCO.19.02105spanning the genetic analysis continuum, from discovery-based6.Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: whole-genome research, through focused research on distinctdevelopment of international criteria for the determination of microsatellite instability in collection of sequences, to precise, sensitive detection of specificcolorectal cancer. Cancer Res. 1998;58(22):5248-5257.sequences, the Applied Biosystems portfolio has the solution7.https://www.thermofisher.com/us/en/home/clinical/clinical-genomics/molecular-oncology-solutions/microsatellite-instability-assay.htmlthat addresses any research needs. For more information,8.https://assets.thermofisher.com/TFS-Assets/GSD/Application-Notes/mlpa-contact your sales representative. assays-seqstudio-genetic-analyzer-app-note.pdf9.Mazoyer S. Genomic rearrangements in the BRCA1 and BRCA2 genes. Hum Mutat. Thermo Fisher Scientific is committed to providing cancer2005;25(5):415-422. doi:10.1002/humu.20169researchers with powerful genetic solutions that enable them to10.Hogervorst FB, Nederlof PM, Gille JJ, et al. Large genomic deletions and duplications pursue the greatest expectations of precision cancer medicine,in the BRCA1 gene identified by a novel quantitative method. Cancer Res. 2003;63(7):1449-1453.ultimately providing more personalized treatment strategies and11.Nygren AO, Ameziane N, Duarte HM, et al. Methylation-specific MLPA (MS-MLPA): better patient outcomes in the future.simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res. 2005;33(14):e128. Published 2005 Aug 16. Thermo Fisher can help you achieve your most exciting cancerdoi:10.1093/nar/gni127research goals with a full range of cancer genomics and12.Skvortsova K, Stirzaker C, Taberlay P. The DNA methylation landscape in cancer. transcriptomics solutions. Essays Biochem. 2019;63(6):797-811. doi:10.1042/EBC2019003713.Huang Y, Liu Y, Zheng C, Shen C. Investigation of cross-contamination Uncover cryptic cancer heterogeneity by qPCR, dPCR, NGS,and misidentification of 278 widely used tumor cell lines. PLoS One. 2017;12(1):e0170384. Published 2017 Jan 20. doi:10.1371/journal.pone.0170384or CE 14.Mastri M, Ramakrishnan S, Shah SD, et al. Patient derived models of bladder cancer Extract precise data from limited and challenging samplesenrich the signal of the tumor cell transcriptome facilitating the analysis of the tumor such as FFPE tissue, precious solid tumor biopsy samples, orcell compartment. Am J Clin Exp Urol. 2021;9(6):416-434. Published 2021 Dec 15.liquid biopsies, by dPCR or qPCR 15.https://www.thermofisher.com/document-connect/document-connect.html?url=https%3A%2F%2Fassets.thermofisher.Obtain key insights from multiple perspectives provided bycom%2FTFS-Assets%2FLSG%2FApplication-Notes%2Fvariant-detection-different technologies tumor-ffpe-samples-sanger-sequencing.pdf16.Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55(4):611-622. doi:10.1373/clinchem.2008.112797Learn more at thermofisher.com/cancerresearch For Research Use Only. Not for use in diagnostic procedures.2022 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. TaqMan is a trademark of Roche Molecular Systems, Inc., used under permission and license. Clinical Pharmacogenetics Implementation Consortium is a trademark of the U.S. Department of Health and Human Services. MLPA is a trademark of MRC Holland B.V. COL020353 0622'